WANY
PTGX icon

Wealthspire Advisors (New York)’s Protagonist Therapeutics PTGX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48
Closed -$3.19K – 2417
2025
Q3 		$3.19K Buy
+48
New +$2.73K ﹤0.01% 2468

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wealthspire Advisors (New York)'s PTGX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 48 shares — an estimated $3.19K sold.

Wealthspire Advisors (New York) first reported a position in PTGX in Q3 2025 and held it in 1 quarter. The position peaked at $3.19K in Q3 2025. 314 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 48 Protagonist Therapeutics shares in Q4 2025, an estimated $3.19K.
  • Wealthspire Advisors (New York) first reported a position in Protagonist Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Protagonist Therapeutics position peaked at $3.19K in Q3 2025.
  • 314 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.